Stephens Investment Management Group LLC Has $76.04 Million Holdings in ResMed Inc. (NYSE:RMD)

Stephens Investment Management Group LLC decreased its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 332,500 shares of the medical equipment provider's stock after selling 4,054 shares during the period. Stephens Investment Management Group LLC owned approximately 0.23% of ResMed worth $76,039,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Peak Financial Advisors LLC acquired a new position in shares of ResMed in the 4th quarter worth approximately $2,972,000. Principal Financial Group Inc. grew its stake in shares of ResMed by 2.9% in the 3rd quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider's stock worth $45,596,000 after purchasing an additional 5,284 shares during the last quarter. Spire Wealth Management grew its stake in shares of ResMed by 11.3% in the 4th quarter. Spire Wealth Management now owns 10,800 shares of the medical equipment provider's stock worth $2,470,000 after purchasing an additional 1,100 shares during the last quarter. Retireful LLC acquired a new position in shares of ResMed in the third quarter worth about $742,000. Finally, Asset Management One Co. Ltd. increased its position in shares of ResMed by 5.1% in the third quarter. Asset Management One Co. Ltd. now owns 58,860 shares of the medical equipment provider's stock worth $14,369,000 after acquiring an additional 2,878 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Stock Down 0.4 %

RMD stock traded down $1.03 during trading hours on Wednesday, hitting $236.40. The company's stock had a trading volume of 674,116 shares, compared to its average volume of 986,927. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $34.72 billion, a PE ratio of 27.91, a price-to-earnings-growth ratio of 1.57 and a beta of 0.70. ResMed Inc. has a 12 month low of $170.56 and a 12 month high of $263.05. The stock has a 50 day moving average price of $238.87 and a two-hundred day moving average price of $238.30.

ResMed (NYSE:RMD - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. On average, equities research analysts expect that ResMed Inc. will post 9.44 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Thursday, February 13th. ResMed's payout ratio is 25.03%.

Insider Transactions at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total transaction of $491,300.00. Following the completion of the transaction, the director now directly owns 81,218 shares in the company, valued at $19,951,201.70. This represents a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the transaction, the chief executive officer now owns 455,472 shares of the company's stock, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,307 shares of company stock worth $4,403,180. 0.71% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Piper Sandler lifted their target price on shares of ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a research report on Friday, January 31st. Royal Bank of Canada lifted their target price on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research report on Friday, October 25th. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research report on Friday, January 31st. Robert W. Baird lifted their target price on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a research report on Thursday, January 16th. They issued a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ResMed currently has a consensus rating of "Moderate Buy" and a consensus price target of $244.73.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.